Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 258013.33%.

  • Lyell Immunopharma's EBITDA Margin fell 1302898000.0% to 258013.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 795656.1%, marking a year-over-year decrease of 4749449900.0%. This contributed to the annual value of 561654.1% for FY2024, which is 3869410200.0% down from last year.
  • Per Lyell Immunopharma's latest filing, its EBITDA Margin stood at 258013.33% for Q3 2025, which was down 1302898000.0% from 534812.5% recorded in Q2 2025.
  • Lyell Immunopharma's EBITDA Margin's 5-year high stood at 12.4% during Q4 2022, with a 5-year trough of 2396633.33% in Q3 2022.
  • Its 5-year average for EBITDA Margin is 481436.95%, with a median of 198620.0% in 2023.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by 2000000000bps in 2022, then skyrocketed by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows Lyell Immunopharma's EBITDA Margin stood at 3021.4% in 2021, then soared by 100bps to 12.4% in 2022, then plummeted by -3215894bps to 398792.31% in 2023, then crashed by -339bps to 1749127.27% in 2024, then surged by 85bps to 258013.33% in 2025.
  • Its EBITDA Margin stands at 258013.33% for Q3 2025, versus 534812.5% for Q2 2025 and 747542.86% for Q1 2025.